Clomipramine

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Other psychedelic; Also: mechanism only.
Half-life: 19–37 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: clomipramine · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

XP · Th

Strongly serotonergic, so blunting is expected in theory; but with LSD, chronic imipramine, desipramine or clomipramine increased the response in all 5 people interviewed (Bonson & Murphy 1996). Dose-related seizures, QTc, anticholinergic effects.

Human data with psilocybin: None with psilocybin; human data with another psychedelic
Half-life: 19–37 h (mean 32 h) / desmethylclomipramine 54–77 h (mean 69 h) (FDA label, checked 2026-09-30)

Evidence types on this record

XPHuman data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

4 listed · counted on reports

Anticholinergic: Blocks acetylcholine. Can cause a fast heart rate, dry mouth, reduced sweating and heat intolerance, and confusion, more so at high doses or in combination. Sources [1]
QT-prolonging: Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [2]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]
Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

03 State rules

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Anafranil ™ (clomipramine hydrochloride) Capsules USP (25 mg, 50 mg, and 75 mg) Rx only · FDA label (DailyMed)
Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry, 15th ed. Wiley, 2025., Tricyclic antidepressants
Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233. — LSD; n=5 on TCAs, all increased

Report an error in this record →